Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica M Franklin

Showing results (21-30 of 144) with videos related to

Pageof 15
Sort By:
Circulation. Cardiovascular Quality and Outcomes|June 15, 2017
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsSpencer Phillips Hey, Jessica M Franklin, Jerry Avorn, et al.
BMJ (Clinical Research Ed.)|June 30, 2016
Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort studyThomas J Hwang, Elisaveta Sokolov, Jessica M Franklin, et al.
Journal of General Internal Medicine|June 26, 2013
Physician trainees' interactions with the pharmaceutical industryKirsten E Austad, Jerry Avorn, Jessica M Franklin, et al.
Epidemiology (Cambridge, Mass.)|February 3, 2015
Evaluating possible confounding by prescriber in comparative effectiveness researchJessica M Franklin, Sebastian Schneeweiss, Krista F Huybrechts, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 14, 2021
Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort studyNicholas Chiu, Julie C Lauffenburger, Jessica M Franklin, et al.
BMJ Quality & Safety|April 27, 2013
Speaking the same language? International variations in the safety information accompanying top-selling prescription drugsAaron S Kesselheim, Jessica M Franklin, Jerry Avorn, et al.
BMJ (Clinical Research Ed.)|September 25, 2015
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyAaron S Kesselheim, Bo Wang, Jessica M Franklin, et al.
Epidemiology (Cambridge, Mass.)|November 19, 2013
Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studiesJessica M Franklin, Jeremy A Rassen, Dorothee B Bartels, et al.
Diabetes Care|June 27, 2019
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus GlimepirideElisabetta Patorno, Sebastian Schneeweiss, Chandrasekar Gopalakrishnan, et al.
Plos One|April 1, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend AnalysisBo Wang, Jessica M Franklin, Wesley Eddings, et al.
Pageof 15

Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
Circulation. Cardiovascular Quality and Outcomes|June 15, 2017
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsSpencer Phillips Hey, Jessica M Franklin, Jerry Avorn, et al.
BMJ (Clinical Research Ed.)|June 30, 2016
Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort studyThomas J Hwang, Elisaveta Sokolov, Jessica M Franklin, et al.
Journal of General Internal Medicine|June 26, 2013
Physician trainees' interactions with the pharmaceutical industryKirsten E Austad, Jerry Avorn, Jessica M Franklin, et al.
Epidemiology (Cambridge, Mass.)|February 3, 2015
Evaluating possible confounding by prescriber in comparative effectiveness researchJessica M Franklin, Sebastian Schneeweiss, Krista F Huybrechts, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 14, 2021
Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort studyNicholas Chiu, Julie C Lauffenburger, Jessica M Franklin, et al.
BMJ Quality & Safety|April 27, 2013
Speaking the same language? International variations in the safety information accompanying top-selling prescription drugsAaron S Kesselheim, Jessica M Franklin, Jerry Avorn, et al.
BMJ (Clinical Research Ed.)|September 25, 2015
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyAaron S Kesselheim, Bo Wang, Jessica M Franklin, et al.
Epidemiology (Cambridge, Mass.)|November 19, 2013
Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studiesJessica M Franklin, Jeremy A Rassen, Dorothee B Bartels, et al.
Diabetes Care|June 27, 2019
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus GlimepirideElisabetta Patorno, Sebastian Schneeweiss, Chandrasekar Gopalakrishnan, et al.
Plos One|April 1, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend AnalysisBo Wang, Jessica M Franklin, Wesley Eddings, et al.
Pageof 15